PT1951272T - Uso de lactobacillus para o tratamento de infeções virais - Google Patents

Uso de lactobacillus para o tratamento de infeções virais

Info

Publication number
PT1951272T
PT1951272T PT67997387T PT06799738T PT1951272T PT 1951272 T PT1951272 T PT 1951272T PT 67997387 T PT67997387 T PT 67997387T PT 06799738 T PT06799738 T PT 06799738T PT 1951272 T PT1951272 T PT 1951272T
Authority
PT
Portugal
Prior art keywords
lactobacillus
treatment
virus infections
infections
virus
Prior art date
Application number
PT67997387T
Other languages
English (en)
Inventor
Alenfall Jan
Berggren Anna
Rask Carola
Wold Agnes
Original Assignee
Probi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi Ab filed Critical Probi Ab
Publication of PT1951272T publication Critical patent/PT1951272T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D13/00—Finished or partly finished bakery products
    • A21D13/40—Products characterised by the type, form or use
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D13/00—Finished or partly finished bakery products
    • A21D13/02—Products made from whole meal; Products containing bran or rough-ground grain
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D13/00—Finished or partly finished bakery products
    • A21D13/06—Products with modified nutritive value, e.g. with modified starch content
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/24—Organic nitrogen compounds
    • A21D2/26—Proteins
    • A21D2/267—Microbial proteins
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D8/00—Methods for preparing or baking dough
    • A21D8/02—Methods for preparing dough; Treating dough prior to baking
    • A21D8/04—Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes
    • A21D8/045—Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes with a leaven or a composition containing acidifying bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/175—Rhamnosus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y10S435/857—Lactobacillus plantarum
PT67997387T 2005-10-06 2006-10-06 Uso de lactobacillus para o tratamento de infeções virais PT1951272T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0502209 2005-10-06
SE0502250 2005-10-07

Publications (1)

Publication Number Publication Date
PT1951272T true PT1951272T (pt) 2016-09-20

Family

ID=37906406

Family Applications (1)

Application Number Title Priority Date Filing Date
PT67997387T PT1951272T (pt) 2005-10-06 2006-10-06 Uso de lactobacillus para o tratamento de infeções virais

Country Status (18)

Country Link
US (3) US8936783B2 (pt)
EP (2) EP1951273B1 (pt)
JP (2) JP5792919B2 (pt)
KR (2) KR101300086B1 (pt)
AU (2) AU2006297895B2 (pt)
BR (2) BRPI0616960B8 (pt)
CA (2) CA2625074C (pt)
CY (1) CY1118006T1 (pt)
DK (2) DK1951272T3 (pt)
ES (2) ES2590916T3 (pt)
HU (1) HUE030542T2 (pt)
IN (2) IN2008DE02606A (pt)
LT (1) LT1951272T (pt)
PL (2) PL1951272T3 (pt)
PT (1) PT1951272T (pt)
RU (2) RU2440123C2 (pt)
SI (1) SI1951272T1 (pt)
WO (3) WO2007040444A1 (pt)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5019961B2 (ja) * 2006-06-26 2012-09-05 株式会社ヤクルト本社 インターロイキン１０産生促進剤
BRPI0719787A2 (pt) 2006-10-02 2014-11-25 Danisco Probióticos para uso na redução da incidência e duração de enfermidade
PL210465B1 (pl) 2007-06-04 2012-01-31 Inst Biotechnologii Surowic I Szczepionek Biomed Społka Akcyjna Zastosowanie kompozycji szczepów z rodzaju Lactobacillus
JP2009057346A (ja) * 2007-09-03 2009-03-19 Kirin Holdings Co Ltd 免疫バランス調節用組成物
FR2922450B1 (fr) * 2007-10-19 2014-06-13 Lallemand Sas Utilisation de bacteries lactique pour la prevention et/ou le traitement de pathologies cutanees
EP2217250A4 (en) 2007-11-09 2011-01-05 California Inst Of Techn IMMUNOREGULATORY COMPOUNDS AND RELATED COMPOSITIONS AND METHODS
EP2153837A1 (en) * 2008-08-14 2010-02-17 Compagnie Gervais Danone Compositions comprising Lactobacillus casei for improving resistance to common infectious diseases
SE533778C2 (sv) 2009-05-14 2011-01-11 Probi Ab Probiotisk fruktdryck
US20100311686A1 (en) * 2009-06-03 2010-12-09 Kasper Lloyd H Nutraceutical composition and methods for preventing or treating multiple sclerosis
WO2011059332A2 (en) 2009-11-16 2011-05-19 Stichting Top Institute Food And Nutrition Improved immunomodulation by probiotics
KR101629525B1 (ko) * 2010-01-11 2016-06-13 이화여자대학교 산학협력단 발효식품에서 유래된 세포밖 소포체를 포함하는 조성물 및 이의 용도
UA109123C2 (uk) * 2010-01-28 2015-07-27 Пробіотична композиція для застосування в лікуванні запалення кишечнику
JP6027961B2 (ja) 2010-04-07 2016-11-16 シェン, ユエSHEN, Yue 粘膜へ化合物を送るための媒体、それに関連する組成物、方法、及びシステム
JP2013530949A (ja) 2010-05-20 2013-08-01 エル ラウンド ジューン 抗原特異的Ｔｒｅｇ並びに関連する組成物、方法及びシステム
CN103458904B (zh) * 2010-12-16 2016-09-28 株式会社明治 格氏乳杆菌的菌体级分在制造用于减轻迟发型变态反应的组合物中的用途
KR101506829B1 (ko) 2010-12-23 2015-03-30 화이자 인코포레이티드 글루카곤 수용체 조절제
WO2012093755A1 (ko) * 2011-01-04 2012-07-12 포항공과대학교 산학협력단 발효식품에서 유래된 세포밖 소포체를 포함하는 조성물 및 이의 용도
LT2673260T (lt) 2011-02-08 2016-10-25 Pfizer Inc. Gliukagono receptoriaus moduliatorius
WO2012133827A1 (ja) * 2011-03-31 2012-10-04 森永乳業株式会社 新規乳酸菌、並びに新規乳酸菌を含有する医薬、飲食品、及び飼料
WO2012141540A2 (ko) * 2011-04-13 2012-10-18 씨제이제일제당 (주) 바이러스 감염 억제 활성을 갖는 신규 분리한 락토바실러스 퍼멘텀 균주
KR101279852B1 (ko) * 2011-06-29 2013-07-09 주식회사 쎌바이오텍 골다공증 예방 또는 치료용 조성물
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
RU2013157388A (ru) 2011-07-22 2015-08-27 Пфайзер Инк. Хинолинильные модуляторы глюкагонового рецептора
US9856451B2 (en) 2011-12-28 2018-01-02 Yamada Bee Company Inc. Lactic acid bacterium having IgA production promoting activity, and use thereof
JP6028962B2 (ja) * 2012-02-16 2016-11-24 国立大学法人金沢大学 ウイルス感染予防乳酸菌組成物及びウイルス感染予防乳酸発酵食品
JP5995593B2 (ja) * 2012-08-02 2016-09-21 丸善製薬株式会社 抗炎症剤
WO2014038929A1 (en) 2012-09-07 2014-03-13 N.V. Nutricia Probiotics for producing antiviral factors
FR2997960B1 (fr) * 2012-11-09 2016-08-05 Inst Nat De La Rech Agronomique (Inra) Nouvelle souche bacterienne de lactobacillus plantarum et utilisation de cette souche
WO2014077365A1 (ja) 2012-11-16 2014-05-22 カルピス株式会社 特定のラクトバチルス・ガセリ株又はその処理物を含有するストレス性腸障害の軽減剤
PL2981274T3 (pl) * 2013-04-03 2020-12-28 Probi Ab Szczepy probiotyczne do stosowania w leczeniu lub zapobieganiu osteoporozie
JP2016521284A (ja) 2013-05-10 2016-07-21 カリフォルニア インスティチュート オブ テクノロジー 大腸ガンのプロバイオティクスによる防止および処置
AU2014288647B8 (en) * 2013-07-12 2015-10-29 Morinaga Milk Industry Co., Ltd. Novel Lactic Acid Bacterium, Drug, Food or Drink, and Feed which Contain the Novel Lactic Acid Bacterium
TWI505831B (zh) * 2013-11-15 2015-11-01 Genmont Biotech Inc 用於治療微小核糖核酸病毒感染的益生菌組合物及其用途
TWI505832B (zh) * 2014-02-21 2015-11-01 Genmont Biotech Inc 乳酸菌、其組合物與彼等於治療自體免疫疾病暨其倂發症之用途
KR101644595B1 (ko) * 2014-07-11 2016-08-03 한국식품연구원 락토바실러스 파라카제이(Lactobacillus paracasei)를 유효성분으로 포함하는 Ｔｈ1-매개 면역 질환 또는 Ｔｈ2-매개 면역 질환의 예방, 개선 또는 치료용 조성물
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
CN113637040A (zh) 2015-08-19 2021-11-12 哈佛学院院长及董事 脂化psa组合物和方法
KR101749222B1 (ko) * 2016-01-04 2017-06-21 주식회사 카브 젖산균을 유효성분으로 포함하는 인플루엔자 바이러스 예방 및 치료용 조성물
GB201600975D0 (en) 2016-01-19 2016-03-02 Probi Ab Novel strain of probiotic bacteria and compositions and uses thereof
NZ744342A (en) * 2016-01-19 2022-11-25 Symrise Ag Probiotics for use as anti-inflammatory agents in the oral cavity
EP3196318A1 (en) 2016-01-19 2017-07-26 Symrise AG Probiotics for altering the composition of oral biofilms
EP3222282A1 (en) * 2016-03-21 2017-09-27 Bionou Research, S.L. Use of probiotics in the treatment and/or prevention of psoriasis
EP3484441A4 (en) 2016-07-15 2020-03-18 President and Fellows of Harvard College GLYCOLIPID COMPOSITIONS AND METHODS OF USE
CN106562462A (zh) * 2016-11-04 2017-04-19 覃贤强 一种富硒保健汤圆及其制备方法
AU2018207946A1 (en) * 2017-01-12 2019-07-25 Probi Ab Probiotic compositions and uses thereof
EP3351259A1 (en) 2017-01-18 2018-07-25 Symrise AG Probiotics for aggregation with disease-associated species in the oral cavity
BR112019015806A2 (pt) * 2017-01-31 2020-03-31 University-Industry Cooperation Group Of Kyung Hee University Bactérias ácido-lácticas inovadoras e uso das mesmas
EP3578637A4 (en) * 2017-01-31 2020-12-16 University - Industry Cooperation Group of Kyung Hee University NEW LACTIC BACTERIA AND THEIR USE
GB201709763D0 (en) * 2017-06-19 2017-08-02 Probi Ab Biological materials and methods
JP6942030B2 (ja) * 2017-11-02 2021-09-29 株式会社ヤクルト本社 抗アレルギー剤感受性判定マーカー
KR102188020B1 (ko) 2018-05-09 2020-12-07 주식회사 고바이오랩 락토바실러스 파라카제이 균주 및 그 용도
KR102138834B1 (ko) 2018-05-23 2020-07-29 주식회사 고바이오랩 락토바실러스 가세리 kbl697 균주 및 그 용도
AU2019289515A1 (en) * 2018-06-18 2021-01-28 Probi Ab Probiotic compositions and uses thereof
WO2019242839A1 (en) * 2018-06-18 2019-12-26 Probi Ab Lactobacillus plantarum compositions and uses thereof
WO2020001747A1 (en) * 2018-06-26 2020-01-02 Symrise Ag Lactobacillus plantarum for skin care
US11058634B2 (en) 2018-11-19 2021-07-13 Steven J. Edwards Adherent oral pharmabiotic delivery strip
EP3896151A4 (en) * 2018-12-12 2022-06-29 Synbio Tech Inc. Use of lactobacillus plantarum twk10 in preparation of composition for resistance to post-exercise inflammation or for reducing body fat
GB201905386D0 (en) * 2019-04-16 2019-05-29 Probi Ab Probiotic compositions and uses thereof
IT201900013740A1 (it) * 2019-08-01 2021-02-01 Nutrilinea S R L Composition comprising S-adenosyl-L-methionine and a probiotic for use to treat depression
JP7195714B2 (ja) * 2020-10-19 2022-12-26 曽根ファーム株式会社 炎症性腸疾患用組成物
CN111035663B (zh) * 2020-01-17 2023-07-14 广州医科大学附属口腔医院（广州医科大学羊城医院） 酸鱼乳杆菌10851在制备治疗多发性硬化的药物中的应用
IT202000007675A1 (it) * 2020-04-09 2021-10-09 Sofar Spa Ivermectina e sue composizioni per uso nel trattamento di infezioni da coronavirus principalmente a carico dell’apparato respiratorio
US20230263845A1 (en) 2020-05-29 2023-08-24 Tohoku University Antiviral Agent
BR112022024911A2 (pt) * 2020-06-06 2022-12-27 Quorum Innovations Llc Materiais e métodos para inibir uma infecção viral, incluindo uma infecção por coronavírus
KR20220091427A (ko) 2020-12-23 2022-06-30 주식회사 리스큐어바이오사이언시스 락토바실러스 사케아이 유래 세포밖 소포체를 유효성분으로 포함하는 자가면역질환의 개선, 예방 또는 치료용 조성물
CN114317343A (zh) * 2021-12-28 2022-04-12 杭州普元生物技术有限公司 一种植物乳杆菌及其在预防和/或治疗中枢神经系统疾病中的应用
CN114085798B (zh) * 2021-12-28 2023-10-31 杭州普元生物技术有限公司 一种植物乳杆菌及其在预防和/或治疗疾病中的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983163A (en) 1981-10-09 1991-01-08 Science Research Center, Inc. Method, compositions and articles for prevention and treatment of herpes simplex virus infections
JPH092959A (ja) * 1995-06-16 1997-01-07 Yakult Honsha Co Ltd ＩｇＥ抗体産生抑制剤および抗アレルギー剤
JP4064481B2 (ja) * 1996-10-11 2008-03-19 ハウスウェルネスフーズ株式会社 免疫賦活剤
JP4163276B2 (ja) * 1998-02-05 2008-10-08 独立行政法人理化学研究所 機能性組成物
JP2002526413A (ja) * 1998-10-01 2002-08-20 プロビ エービー 酸化性ストレス因子の減少
EP1020123A1 (en) * 1999-01-18 2000-07-19 Sitia-Yomo S.p.A. Beverages containing live lactic bacteria
WO2000053202A1 (en) * 1999-03-11 2000-09-14 Societe Des Produits Nestle S.A. Lactobacillus strains capable of preventing diarrhoea caused by pathogenic bacteria and rotaviruses
IT1306716B1 (it) * 1999-06-21 2001-10-02 Mendes S U R L Associazione di batteri lattici e suo uso per la prevenzione e/o iltrattamento terapeutico di infezioni e di stati infiammatori.
EP1084709A1 (en) * 1999-09-17 2001-03-21 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Oral recombinant lactobacilli vaccines
US6696057B1 (en) 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
SE0003045D0 (sv) * 2000-08-29 2000-08-29 Probi Ab New method
SE0003100D0 (sv) * 2000-09-01 2000-09-01 Probi Ab New strains
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
US20040241149A1 (en) * 2001-09-05 2004-12-02 Claudio De Simone Use of unmethylatd cpg
US20040022775A1 (en) * 2002-04-15 2004-02-05 Gregor Reid Methods of treating viral infections in mammals
US20040002275A1 (en) * 2002-06-28 2004-01-01 Niranjan Thakore Fabric reinforced rubber product
JP4034632B2 (ja) * 2002-10-01 2008-01-16 ハウスウェルネスフーズ株式会社 乳酸菌含有炊飯用組成物
SE526711C2 (sv) * 2003-01-31 2005-10-25 Probi Ab Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
WO2004076615A2 (en) 2003-02-27 2004-09-10 Bioneer A/S Immunomodulating probiotic compounds
SE527555C2 (sv) * 2003-04-04 2006-04-11 Probi Ab Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar
CA2526158A1 (en) * 2003-05-22 2004-12-02 Synbiotics Ab A probiotic composition comprising at least two lactic acid bacterial strains which are able to colonise the gastrointestinal tracts in combination with having intestinal survivalproperty, intestinal binding property, an infection protection property and a fiber fermenting property
WO2005007834A1 (en) * 2003-07-23 2005-01-27 Probionic Corp. Acid tolerant probiotic lactobacillus plantarum probio-38 that can suppress the growth of pathogenic microorganism and tge coronavirus
EP1661983B1 (en) * 2003-08-21 2011-01-05 Otsuka Pharmaceutical Co., Ltd. Lactic acid bacteria having mucosal immunopotentiation effect
SE0400355D0 (sv) * 2004-02-17 2004-02-17 Synbiotics Ab New synbiotec use
SE528382C2 (sv) * 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
EP1814514A2 (en) * 2004-11-25 2007-08-08 Unilever Naamloze Vennootschap Heavy chain and single domain antibodies

Also Published As

Publication number Publication date
BRPI0616960A2 (pt) 2011-07-05
LT1951272T (lt) 2016-10-10
KR101300077B1 (ko) 2013-08-30
WO2007040446A1 (en) 2007-04-12
JP5792919B2 (ja) 2015-10-14
HUE030542T2 (en) 2017-05-29
IN2008DE02592A (pt) 2008-07-04
SI1951272T1 (sl) 2016-10-28
PL1951273T3 (pl) 2014-07-31
RU2440123C2 (ru) 2012-01-20
KR101300086B1 (ko) 2013-08-30
EP1951273B1 (en) 2014-02-12
EP1951272B1 (en) 2016-06-15
PL1951272T3 (pl) 2016-12-30
US20130017261A1 (en) 2013-01-17
WO2007040444A1 (en) 2007-04-12
AU2006297896B2 (en) 2011-12-08
US8936783B2 (en) 2015-01-20
RU2417092C2 (ru) 2011-04-27
US8420376B2 (en) 2013-04-16
US20100034877A1 (en) 2010-02-11
BRPI0616960B8 (pt) 2021-05-25
AU2006297895B2 (en) 2011-09-01
CA2625074A1 (en) 2007-04-12
KR20080080981A (ko) 2008-09-05
JP2009511470A (ja) 2009-03-19
RU2008118007A (ru) 2009-11-20
ES2460891T3 (es) 2014-05-14
BRPI0616962B8 (pt) 2021-05-25
AU2006297896A1 (en) 2007-04-12
EP1951273A1 (en) 2008-08-06
BRPI0616960B1 (pt) 2019-10-08
AU2006297895A1 (en) 2007-04-12
US8691214B2 (en) 2014-04-08
DK1951272T3 (en) 2016-09-19
CA2625074C (en) 2016-05-10
CA2624660A1 (en) 2007-04-12
DK1951273T3 (da) 2014-05-05
ES2590916T3 (es) 2016-11-24
CY1118006T1 (el) 2017-05-17
RU2008118008A (ru) 2009-11-20
EP1951272A1 (en) 2008-08-06
CA2624660C (en) 2016-07-12
JP5419455B2 (ja) 2014-02-19
BRPI0616962B1 (pt) 2019-09-17
EP1951272A4 (en) 2010-01-27
EP1951273A4 (en) 2010-02-17
BRPI0616962A2 (pt) 2011-07-05
JP2009511471A (ja) 2009-03-19
KR20080081146A (ko) 2008-09-08
WO2007040445A1 (en) 2007-04-12
IN2008DE02606A (pt) 2008-07-04
US20090208469A1 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
EP1951272A4 (en) USE OF LACTOBACILLUS FOR THE TREATMENT OF VIRAL INFECTIONS
ZA200802934B (en) Use of lactobacillus for treatment of virus infections
IL257622B (en) Methods and preparations for the treatment of persistent infections
IL250858A0 (en) Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
HK1221956A1 (zh) 用於治療感染的鹵代類苯酞化硼
HK1134679A1 (zh) 用於治療感染的組合物和方法
ZA200709727B (en) Compounds and methods for the treatment of prevention of flavivirus infections
IL200116A0 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
IL179873A0 (en) Methods of treatment of endobronchial infections
EP1865967A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND OTHER DISEASES
HK1156038A1 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
IL195272A0 (en) Methods and compositions for the treatment of viral infections
IL182785A0 (en) Particles for treatment of pulmonary infection
GB0513096D0 (en) Treatment of microbial infections
GB2411354B (en) Use of Scutellaria for the treatment of viral infections
PL2132215T3 (pl) Związki do zapobiegania lub leczenia zakażeń wirusowych i sposoby ich stosowania
ZA200904068B (en) Anti-tsg101 antibodies and their uses for treatment of viral infections
IL180459A0 (en) Treatment of bacterial infections
PL2117563T3 (pl) Zastosowanie antybiotyków amidynoantracyklinowych do leczenia infekcji wirusowych
ZA200800201B (en) Composition and the use thereof for the treatment of viral infections
GB0518003D0 (en) Treatment of hepatatis c
GB0622841D0 (en) Treatment of staphylococcal infections